Showing 20 of 84 recruiting trials for “non-hodgkin-lymphoma”
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
👨⚕️ Lapo Alinari, MD, PhD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Mar 2023View details ↗
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
👨⚕️ Armin Ghobadi, M.D., Washington University School of Medicine📍 1 site📅 Started Dec 2022View details ↗
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
👨⚕️ Catherine S Diefenbach, Laura and Isaac Perlmutter Cancer Center at NYU Langone📍 9 sites📅 Started Nov 2022View details ↗
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 31 sites📅 Started Aug 2022View details ↗
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
👨⚕️ Wenbin Qian, 2nd Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Jul 2022View details ↗
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
👨⚕️ Kristie Blum, MD, Emory University Hospital/Winship Cancer Institute📍 2 sites📅 Started May 2022View details ↗
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
👨⚕️ Ryan Lynch, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Oct 2020View details ↗
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
👨⚕️ Sarit Assouline, The Jewish General Hospital, Montreal QC, Canada📍 4 sites📅 Started Sep 2020View details ↗
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →